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When chemotherapy is used in androgen-independent prostate cancer (AIPC), androgen deprivation is continued despite its failure.
In this study, we investigated whether it was possible to re-induce hormone sensitivity in previously castrate patients by stopping
endocrine therapy during chemotherapy. A phase II prospective study investigated the effects of reintroduction of endocrine therapy
after oral chemotherapy in 56 patients with AIPC, which was given without concurrent androgen deprivation. After chemotherapy,
patients were given maximum androgen blockade until failure when treatment was switched to diethylstilbestrol and dexamethasone.
Patients had already received these endocrine treatments in the same sequence before chemotherapy. All patients were castrate at
the start of chemotherapy. Forty-three subsequently restarted endocrine therapy after the completion of chemotherapy. The median
overall survival for these 43 patients from the time of restarting endocrine therapy was 7.7 months (95% confidence interval (CI):
3.7–10.9 months). Sixteen (37%) patients had a 50% PSA response to treatment, which was associated with improved overall
survival (14.0 months vs 3.7 months P¼0.003). Eight out of 12 patients who did not respond to diethylstilbestrol before
chemotherapy did so post chemotherapy. Re-induction of hormone sensitivity can occur after chemotherapy in AIPC.
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There is an increasing number treatment options for androgen-
independent prostate cancer (AIPC). Responses have been seen to
steroids and estrogens (Farrugia et al, 2000; Nishimura et al, 2000),
and chemotherapy has shown a survival advantage for these
patients (Petrylak et al, 2004; Tannock et al, 2004). Until recently,
it has been a universal practice to continue androgen deprivation
during chemotherapy, despite previous progression on this
treatment. Obviously, stopping treatment could result in restora-
tion of androgen levels and growth of androgen-sensitive clones.
However preclinical data suggest that chemotherapy in AIPC cell
lines is more effective if given sequentially rather than concur-
rently (Tang et al, 2006). Additionally, in breast cancer, sequential
hormone therapy and chemotherapy might be advantageous
(Cavalli et al, 1983; Kim et al, 2005).
In a previous chemotherapy study involving castrate patients
AIPC, we anecdotally observed that re-induction of hormone
sensitivity was possible if endocrine therapy was stopped during
chemotherapy (Shamash et al, 2005). Therefore, a prospective
phase II study was designed to investigate this observation.
MATERIALS AND METHODS
Between May 2003 and January 2006, castrate patients (testoster-
one o1.5nmoll
 1) with AIPC, who had in addition also failed
diethylstilbestrol (1mg) and dexamethasone (2mg), were recruited
into this study. All patients received oral chemotherapy with
chlorambucil 1mgkg
 1 starting day 1, lomustine 2mgkg
 1 day 1,
etoposide 50mg daily from day 22–28 and 36–42, with the cycle
repeating every 56 days. This treatment was based on a previously
published regimen (Shamash et al, 2005). Patients were biochemi-
cally castrate (testosterone o1.5nmoll
 1 or failed maximum
androgen blockade (MAB)) before starting the chemotherapy. All
endocrine therapy was stopped during chemotherapy.
The entry criteria required for this study included histologic
verification of prostate cancer, prostate-specific antigen (PSA)
progression of disease despite failure of androgen deprivation and
subsequent oestrogen (diethylstilbestrol 1mg at least or equiva-
lent) and corticosteroid (dexamethasone 2mg or equivalent). This
study was approved by the ethics committee and patients gave
written informed consent before therapy.
Following failure of chemotherapy, patients recommenced
endocrine therapy, initially with MAB (bicalutamide and GnRH
analogue), and when this failed, patients were given dexametha-
sone 2mg daily and diethylstilbestrol 1mg daily (DS). Patients
were seen monthly with PSA measurement, clinical and toxicity
assessment.
In this study, progression of disease was based on PSA, using the
Prostate-Specific Antigen Working Group criteria published in
1999 throughout (Bubley et al, 1999).
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sThirteen of the 56 chemotherapy patients in this study did
not restart endocrine therapy at the time of progression on
chemotherapy. Twelve of these patients died of progression of
disease before reintroduction of endocrine therapy could occur,
and one refused to go back on endocrine therapy.
The log-rank test was used to look at which categorical variables
were significant on univariate analysis for overall survival at the
time of reintroduction of hormone therapy. Multivariate analysis
was performed by fitting a Cox proportional hazard model to the
data.
The Mann–Whitney two-sample statistic was used to compare
median values between groups. Frequency tables and proportions
were examined using Fisher’s exact test.
RESULTS
Forty-three patients with AIPC went on to receive further
endocrine therapy after disease progression on chemotherapy.
The characteristics of these patients are shown in Table 1, Figure 1.
The median overall survival for these patients, from the time of
restarting endocrine therapy, was 7.7 months (95% CI: 3.7–10.9
months).
Twenty-two patients (51%) were non-castrate (testosterone
41.5nmoll
 1) at the start of endocrine therapy. Median overall
survival for the non-castrate patients was 8.7 months (95% CI:
3.3–20.0) vs 6.4 months (95% CI: 2.6–12.1) for the castrate
patients (P¼0.33).
Sixteen of the 43 patients (37%) had a PSA response to
treatment (either MAB or DS, which was associated with better
overall survival compared with those with no PSA response (14.0
months (95% CI: 6.3–26.4) vs 3.7 months (95% CI: 2.1–8.7):
P¼0.003).
The median PSA progression free survival on MAB after
chemotherapy was 1.7 months (range: 0.3–9.7 months). Eight
(19%) patients had a PSA response to MAB, and these responders
were on treatment for a median of 3.9 months (range 0.4–6.8).
Two of 17 (12%) biochemically castrate patients had a PSA
response to MAB, while six of 22 (27%) non-castrate patients had a
PSA response to MAB (P¼0.43).
Twenty-eight patients (65%) of the cohort went on to subsequently
receive DS after MAB. The remainder did not receive DS because of
contraindications to treatment or rapid disease progression on MAB.
The median survival from the time of starting DS was 9.8 months
(95% CI: 5.5–16.4). Twelve (43%) of these patients had a PSA
response. Obtaining a PSA response to DS was associated with
improved survival (median overall survival 16.5 months (95%CI: 6.9
to infinity) vs 5.5 months (95% CI: 2.7–13.3) (P¼0.02). Overall, four
patients responded to both MAB and DS.
Table 1 The characteristics of patients receiving endocrine therapy after
chemotherapy in this study
Number 43
Median age 72 (range: 50–86)
Median PSA at the start of chemotherapy 144 (range: 2.1–981)
PSA at the time of chemotherapy progression 221 (11.5–3621)
Survival from time of androgen independence
(months)
31.5 (95% CI: 20.3–43.5)
Time from androgen independence to starting
chemotherapy (months)
14.6 (95% CI 10.5–19.0)
Duration on chemotherapy (months) 3.3 (2.5–4.6)
Performance status at start of
0–2 months 29 (67%)
3 months 14 (33%)
Presence of metastatic disease 26 (76%)
Gleason score
2–7 24
8–10 19
Endocrine status at the end of chemotherapy:
Castrate 15 (35%)
Non-castrate 21 (49%)
Unknown 7 (16%)
Response to chemotherapy (50% PSA response) 8 (19%)
Median survival from the end of chemotherapy 7.0 (4.2–11)
CI¼confidence interval; PSA¼prostate-specific antigen.
Response (N=16)
No response (N=27)
P=0.003
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Overall survival by response to further hormone therapy after chemotherapy
Figure 1 Kaplan–Meier curve comparing the outcome of patients with and without a 50% PSA response at reintroduction of hormone therapy (either
MAB or diethylstilbestrol).
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sThe response to DS was independent of whether or not the
patients were castrate at the end of chemotherapy (4/13 vs 8/14
(P¼0.25)). Eight out of 12 patients who did not respond to DS
before chemotherapy subsequently responded when rechallenged.
In multivariate analysis, the established prognostic factors
(Gleason score, PSA at diagnosis, presence of bone metastasis)
were unable to predict the likelihood of further hormone response
following failure of chemotherapy.
DISCUSSION
These prospective data confirm our anecdotal observation and
suggest that endocrine sensitivity can be reintroduced by stopping
endocrine therapy during chemotherapy for AIPC. Therefore,
stopping endocrine therapy during chemotherapy may not be
harmful, especially for the subset of patients who respond to it a
second time. Randomised studies are required to answer this
question formally.
It is intriguing that a group of patients should respond to
endocrine therapy for a second time. This includes biochemically
castrate and non-castrate patients, which suggests that when
progression of disease occurs during chemotherapy, in the absence
of concurrent androgen deprivation, both hormone-dependent
and -independent clones may be responsible for the tumour
regrowth. Therefore, it appears that chemotherapy may alter the
subsequent behaviour of the disease. This theory is supported by
the observation that some patients responded to DS after but not
before chemotherapy. Additionally, patients who remained bio-
chemically castrate after chemotherapy were less likely to respond
to MAB than those who were not. Nevertheless, a large proportion
of this group responded to DS, which was the treatment they
received immediately before chemotherapy.
One of the possible confounding factors of this work is that
patients responding to endocrine therapy a second time may have
more indolent tumours and the PSA response is irrelevant.
However, the PSA doubling time before chemotherapy did not
correlate with a subsequent response to endocrine therapy (52 vs
57 days (P¼0.60)).
There are a number of postulated mechanisms for the develop-
ment of androgen independence in prostate cancer, including
mutations of the androgen receptor to allowing other molecules to
bind to it (Grossmann et al, 2001). There are in vitro data to suggest
that this may be the case with diethylstilbestrol (Kalach et al, 2005).
It may be that the prostate cancer cells, which regrow during
chemotherapy in the presence of androgen ablation therapy, have
molecular characteristics different from those for which chemo-
therapy is given alone. It is even possible that removing hormonal
suppression during chemotherapy may allow cells to enter the cell
cycle and become more sensitive to cytotoxic drugs.
A shortcoming of this work was that it did not use docetaxel
chemotherapy, which has become the standard treatment for these
patients. However, the case report published in this edition of
the British Journal of Cancer suggests this may be possible with
docetaxel and requires further investigation.
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